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Abstract--Familial hypercholesterolem& (FH) is an inherited deficiency of  LDL  receptors that 
has been an important model for liver-directed gene therapy. We are developing approaches for 
treating F H  that are based on direct delivery of  recombinant L D L  receptor genes to liver in vivo. As  
a first step towards this goal, replication-defective recombinant adenoviruses were constructed 
which contained either the lacZ gene or the human L D L  receptor cDNA expressed from a [3-actin 
promoter. Primary cultures of  hepatocytes were established from two patients with homozygous FH 
and one nonFH patient, and subsequently exposed to recombinant adenoviruses at ;viOls ranging 
from O.l to 5. Essentially all of  the cells expressed high levels o f  the transgene without demonstrable 
expression of  an early or late adenoviral gene product," the level of  recombinant-derived LDL  
receptor protein in transduced FH hepatocytes exceeded the endogenous levels by at least 20-fold. 
These studies support the utility of  recombinant adenoviruses for efficient transduction of  
recombinant L D L  receptor genes into human F H  hepatocytes without expression of  viral proteins. 
INTRODUCTION 
Familial hypercholesterolemia (FH) is 
an autosomal dominant disease caused by 
defects in the gene encoding LDL receptor 
(1). Patients who inherit two abnormal LDL 
receptor alleles provide an excellent model 
for the early development of gene replace- 
ment therapies. Homozygous FH is truly a 
lethal disease with patients developing life- 
threatening coronary heart disease (CHD) in 
childhood due to massive accumulations of 
LDL that are refractory to traditional phar- 
macological therapies. Metabolic correction 
has been achieved in FH homozygotes by 
orthotopic liver transplantation, indicating 
that selective correction of LDL receptor 
expression in hepatocytes by liver-directed 
gene therapy should be sufficient for improve- 
ment in hypercholesterolernia (2-4). The 
observation that FH homozygotes with re- 
sidual LDL receptor activity have a better 
prognosis than those with null genotypes 
suggests that partial genetic correction may 
be therapeutic (1). Finally, the availability of 
an authentic animal model for FH, the 
Watanabe heritable hypertipidemic (WHHL) 
rabbit, greatly facilitates the evaluation of 
new genetic therapies (5-7). 
The early paradigm for gene therapy of 
FH was based on transplantation of autolo- 
gous hepatocytes transduced with recombi- 
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nant retroviruses ex vivo. The feasibility of 
this model of liver-directed gene therapy has 
been demonstrated in the WHHL rabbit (8); 
animals treated with ex vivo gene therapy 
realized a 25-40% diminution in serum 
cholesterol that lasted for the duration of the 
experiment (four months). Based on addi- 
tional safety experiments in dogs (9) and 
baboons (10), a clinical protocol for the 
treatment of symptomatic FH homozygotes 
by ex vivo liver-directed gene therapy was 
designed and initiated. This approach, how- 
ever, has several inherent limitations. The 
therapy requires a minimum of one major 
surgical procedure with the attendant risks. 
Furthermore, the efficacy is necessarily lim- 
ited by the number of hepatocytes that can 
be harvested, manipulated ex vivo, and 
transplanted, which has never been greater 
than 5% of the total cells in liver (8). Finally, 
the complexity of the protocol severely 
restricts its application. 
A more practical and potentially effec- 
tive approach to gene therapy of FH is direct 
delivery of the gene to hepatocytes in vivo. 
This has been accomplished in the WHHL 
rabbit by infusion of synthetic molecular 
conjugates that are tropic for hepatocytes 
(11). However, the level of recombinant gene 
expression achieved in recipient animals was 
low and the effect was transient. Another 
potential approach to in vivo liver-directed 
gene therapy utilizes replication defective 
recombinant adenoviruses (12). Important 
advantages of adenoviruses for gene transfer 
to the liver include: (1) virus is easily purified 
at high concentrations (i.e., approximately 
1013 particles/ml), and (2) gene transfer can 
be accomplished in nondividing cells. The 
utility of recombinant adenoviruses for in 
vivo gene therapy was first demonstrated in a 
mousemodel  of the liver metabolic disease 
caused by ornithine transcarbamylase defi- 
ciency (13). A similar approach has been 
used to deliver recombinant reporter genes 
to rat liver (14) and a human LDL receptor 
gene to mouse liver (15). 
We describe in this report an important 
step toward the development of in vivo gene 
therapy of FH with recombinant adenovi- 
ruses. Primary cultures of hepatocytes from 
patients with homozygous FH were corrected 
without apparent toxicity by single exposure 
to low concentrations of recombinant virus. 
MATERIALS AND METHODS 
Recombinant Adenoviruses. The plas- 
mids used to generate the recombinant, 
El-deleted adenoviruses Ad.CBIacZ and 
Ad.CBhLDLR were constructed as follows. 
The plasmid CMV~AIacZ (10) was digested 
with SnaBI and Nhel, and gag[3AhLDLR 
(16) was digested with Nhel and then 
partially digested with Xhol to isolate a 
fragments containing the [3-actin promoter 
and either the lacZ gene or the human LDL 
receptor cDNA. These fragments were blunt- 
ended with Klenow. The plasmid pAdCMV- 
lacZ (17) was digested with SnaBI and Notl 
to remove the CMV promoter and lacZ gene 
(retaining the CMV enhancer), blunt-ended 
with Klenow, and Iigated with inserts contain- 
ing the [3-actin promoter fused to either the 
lacZ or LDLR genes. The resulting vectors 
were designated pAdCBlacZ and pAd- 
CBhLDLR, respectively. 
Plasmids were linearized with Nhel and 
cotransfected into 293 cells with wild-type 
adenoviral DNA [strain sub360 (18), which 
contains a partial E3 deletion] that had been 
digested with Xbal and Clal to remove the 5' 
ITR. Recombinant adenoviruses were iso- 
lated following transfection (19), subjected 
to two rounds of plaque purification, and 
lysates were purified by cesium chloride 
centrifugation (20). The viral stocks were 
evaluated for titer by limiting dilution plaque 
assay on 293 cells and stored at -20°C after 
diluting fourtbld with 10 mM Tris CI, pH 8.1, 
100 mM NaCI, 0.1% bovine serum albumin, 
and 50% glycerol. Titers of the glycerol 
stocks were: Ad.CBlacZ, 2.4 × 109 plaque- 
Adenovirus-Mediated Complementation in FH Hepatocytes 451 
forming units (PFU)/ml; Ad.CBhLDLR, 4 x 
109 PFU/ml; wild-type Ad, 8 x 109 PFU/ml. 
Isolation and Propagation of Hepatocytes. 
Hepatocytes were isolated from liver tissue 
by in situ perfusion of collagenase as de- 
scribed (21). Cells were plated at a density of 
4 x 106 cells/10 cm 2 plate in Hormonally 
defined medium (HDM) supplemented with 
10% FCS overnight and subsequently main- 
tained in HDM alone. 
Electron Microscopy. Plates of hepato- 
cytes were fixed 24, 48, and 72 h after plating 
in 1.6% formaldehyde/2% gluteraldehyde in 
0.1 M cacodylate buffer for 1 h at 4°C, then 
washed in 0.1 M cacodylate, and postfixed in 
1.5% osmium tetroxide in 0.1 M cacodylate 
buffer for 30 min at 4°C. Samples were 
processed, stained, and analyzed by transmis- 
sion electron microscopy as described (22). 
Hepatocyte Infection. NonFH and FH 
hepatocytes plated in HDM (without serum) 
were infected with purified recombinant 
adenovirus [multiplicity of infection 
(MOI) = 0.1, 1, or 10] one to three days after 
plating; an estimate of cell number, based on 
inspection of the plate, was used to calculate 
the MOI. Two days following infection the 
ceils were analyzed for lacZ or LDL receptor 
expression as described below. 
CytochemicalAnalyses. Plates of hepato- 
cytes were analyzed for [3-galactosidase ex- 
pression using the X-gal histochemical stain 
(23) and for LDL receptor activity using an 
in situ activity assay based on the uptake of 
fluorescent labeled ligand. The LDL recep- 
tor assay was performed as follows. Hepato- 
cytes were incubated with DMEM supple- 
mented with 10% calf lipoprotein-deficient 
serum and 10 Ixg/mt of LDL labeled with the 
fluorescent probe l,l'-dioctadecyl-3,3,3',3'- 
tetramethyl indocarbocyanine perchloridate 
(diI-LDL; gift of Bruce Auerbach, Parke- 
Davis, Ann Arbor, Michigan). Following a 
4-h incubation, cells were rinsed with DMEM 
and diI-LDL uptake was visualized by fluores- 
cent microscopy as described (16). 
Expression of the adenoviral genes 
encoding DNA binding protein (DBP) and 
fiber protein was evaluated using immunocy- 
tochemical techniques with antibodies to the 
respective protein products, anti-DBP, a gift 
of A. Levine (Princeton University, Prince- 
ton, New Jersey), and anti-fiber (805F), from 
Chemicon International, Inc. (Temecula, 
California). The 293 cells plated on cover 
slips, infected with recombinant adenovirus 
(MOI = 1), and harvested 16 h postinfection 
were used as a positive control for early and 
late adenoviral gene expression. Hepatocytes 
were plated in 60-ram tissue culture dishes 
and infected the following day with wild-type 
adenovirus or with Ad.CBlacZ at a MOI of 1. 
The cells were harvested 18 h later by 
scraping with a rubber policeman, gently 
pelleted, suspended in OCT, and quick- 
frozen. Cells on cover slips (293 cells) or 
fresh-frozen sections (hepatocytes) were fixed 
by immersion in methanol at -20°C for 10 
min and stored at -80°C. Samples were 
rehydrated in PBS and incubated serially 
with PBS containing 10% normal goat serum, 
primary antibodies diluted 1:20 (anti-DBP) 
or 1.:10 (anti-fiber) in PBS/10% goat serum 
(30 min), and peroxidase-conjugated goat 
anti-mouse Ig (Jackson Immunoresearch, 
West Grove, Pennsylvania) diluted 1:200 in 
PBS/10% goat serum (60 min). Samples 
were washed in PBS, incubated with the 
AEC color reagent for 4 min, and stained in 
hematoxylin tbr 1 rain. 
Western Blot Analysis. Hepatocytes were 
rinsed with PBS, scraped from the dish using 
a rubber policeman, and pelleted cells were 
stored at -70°C. Cells were sotubilized by 
suspension in buffer containing 20 mM Tris 
C1, pH 8, 1 mM CaC12, 0.15 M NaCt, 1% 
Triton X-100, and a mixture of protease 
inhibitors (1 mM phenylmethylsulfonyl fluo- 
ride, 0.t mg/ml Ieupeptin, 0.2 mg/ml soy- 
bean trypsin inhibitor, 0.1 mg/ml chy- 
mostatin, and 0.1 mg/ml aprotinin). Following 
a 1-h incubation on ice, insoluble material 
was removed by centrifugation at 4°C, and 
the protein concentration of the supernatant 
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was determined using the BioRad DC kit. 
Equal amounts of protein (68 l~g in FH2 
experiment and 90 ~g in FH3 experiment) 
were loaded in each lane of an SDS-6% 
polyacrylamide gel in the absence of boiling 
or reducing agents. Purified [3-galactosidase 
(Sigma Chemical Co., St. Louis, Missouri) 
was included as a positive control, and for 
comparison, 100 Ixg (in FH2 experiment) or 
200 ~xg (FH3) of an extract prepared from 
normal human liver as previously described 
(24) was also included. The gel was trans- 
ferred to nitrocellulose and the filters probed 
(24). The antibodies used were a monoclonal 
anti-[3-galactosidase antibody (IgG1) from 
Sigma, diluted 1:500, and a monoclonal 
anti-human LDLR antibody (IgG1) from 
Amersham (Arlington Heights, Illinois), di- 
luted to I Ixg/ml. Following incubation with a 
peroxidase-conjugated goat anti-mouse IgG 
antibody diluted 1:1000, the filters were 
washed, then incubated with ECL (Amer- 
sham) according to the manufacturer's direc- 
tions, and exposed to Kodak XAR-5 X-ray 
film. 
RESULTS AND DISCUSSION 
The design of safe and efficient methods 
for delivering recombinant genes to hepato- 
cytes in vivo would greatly enhance the utility 
of liver-directed gene therapy. Previous 
attempts using liposomes (25) or DNA/ 
protein complexes (11, 26) resulted in levels 
of expression that were inadequate for 
therapeutic effects. Direct infusion of recom- 
binant retroviruses into the portal vein after 
partial hepatectomy is associated with gene 
transfer in only a few percent of hepatocytes 
(27). Experiments with rats and mice indi- 
cate that infusion of recombinant adenovi- 
ruses in the absence of partial hepatectomy 
or injury to the liver is associated with 
high-level transgene expression in the major- 
ity of hepatocytes (13-15, and unpublished 
data). In this report, we explore the feasibil- 
ity of using recombinant adenoviruses to 
correct a genetic deficiency of LDL receptor 
in primary" hepatocytes of patients with FH. 
Hepatocytes were isolated from liver 
tissue of a normal donor (Z8) and two FH 
patients (FH2 and FH3). A summary of the 
salient features of the patients and the cell 
isolations is provided in Table 1. A portion of 
a donor liver from a nonFH patient that was 
surgically reduced prior to transplantation 
was used as a source of normal hepatocytes. 
Hepatocytes from two FH patients (desig- 
nated FH2 and FH3) were isolated from 
freshly resected liver that was used for ex vivo 
gene therapy; additional plates of cells not 
suitable for transplantation were used in 
these experiments. The recovery of hepato- 
cytes from the collagenase perfusions ranged 
from 4.4 to 20 x 106 cells/g wet weight of 
tissue with a viability of 92-93%. Cells were 
maintained in culture for four days. Repre- 
sentative electron photomicrographs of cells 
from FH3 are presented in Fig. 1. Greater 
than 95% of the cells retained ultrastructural 
features specific to hepatocytes for the 
duration of the experiment, confirming the 
purity of the preparation and the stability of 
the cultures in terms of hepatocyte differen- 
tiation. This experience with hepatocytes 
from FH patients is consistent with our 
previous studies with liver from four nonFH 
patients (21). 
Table 1. Summary of Hepatocyte Isolations 
Cell isolation 
Patient  Age Sex Clinical status Liver mass  (g) Cell (N) Viability (%) 
Z8 37 M NonFH donor 156 0.7 x 109 92 
FH2 12 M FH 230 4.6 x 109 92 
FH3 7 F FH 187 2.9 × 109 93 
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Fig, 1. Electron micrographs of cultured FH hepatocytes. Cultures of hepatocytes from FH3 were harvested one 
(panel A), two (panel B), and three (panel C) days after plating, fixed, and analyzed by transmission electron 
microscopy. Photomicrographs of representative cells are presented. 
Conditions required for efficient adeno- 
virus-mediated gene transfer were estab- 
lished with normal hepatocytes using the 
Ad.CBlacZ virus. Purified virus was diluted 
into HDM and added directly to the cultured 
hepatocytes 24-72 h after plating; cells were 
harvested for evaluation of transgene expres- 
sion 24 h later. Figure 2 presents X-gal 
histochemistry of normal hepatocytes that 
were mock infected (panel A) or infected 
with Ad.CBlacZ at an MOI of 0.1 (panel B) 
and 1.0 (panel C). The efficiency of gene 
transfer was directly proportional to the 
concentration of virus added to the medium 
with essentially 100% of the cells expressing 
high levels of lacZ when cells were exposed 
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Fig. 2. X-gal histochemistry of infected hepatocytes. Normal human hepatocytes were infected two days after plating 
with Ad.CBhLDLR at a MOI of 1 (A), or with Ad.CBlacZ at a MOI of 0.1 (B) or 1 (C), and stained one day 
postinfection with X-gal. 
to  virus  at  an M O I  of  1 wi thou t  a p p a r e n t  
cy topa th ic  effects. A d d i t i o n a l  expe r imen t s  
have d e m o n s t r a t e d  tha t  cy topa tho logy  does  
not  occur  unt i l  the  M O I  is equa l  to or  g rea t e r  
t han  50 ( d a t a  not  shown).  
H e p a t o c y t e s  f rom the  two F H  pa t i en t s  
were exposed to Ad.CBlacZ and A d . C B h L D L R  
at M O I s  equal  to 1 and  10, and  whole  cell 
lysates were  ana lyzed  for [3-galactosidase and  
L D L  r e c e p t o r  by W e s t e r n  blot  analysis  
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(Fig. 3). Analysis with antibody to [3-galac- 
tosidase revealed a predominant band at 
116 kDa that was specific to lysates from 
Ad.CMVlacZ-infected cells and comigrated 
with purified [3-galactosidase enzyme. Analy- 
sis with a monoclonal antibody to human 
LDL receptor revealed a 130-kDa band in 
lysates from liver and cultured hepatocytes of 
a normal donor. This was not present in 
cultured hepatocytes from either FH patient, 
indicating their mutations are associated 
with quantitative defects in LDL receptor 
expression. In contrast, extremely high quan- 
tities of LDL receptor protein were detected 
in lysates of FH hepato~-te s exposed to the 
Ad.CBhLDLR virus; the level of recombi- 
nant LDL receptor protein in ceils infected 
at an MOI of 10 exceeded the levels in 
nonFH liver or hepatocytes by at Ieast 
20-fotd. 
Fig. 3. Western blot analysis of infected hepatocytes, kysates were prepared from infected cells and were subjected 
to SDS-PAGE followed by transfer to nitrocellulose. Filters were incubated with either an anti-13-galactosidase 
monoclonal antibody (left panels) or with an anti-human LDL receptor monoclonat antibody (right panels). !3-gal, 
purified 13-galactosidase; lacZ 1 and lacZ 10, FH hepatocytes infected with Ad.CBlacZ at MOIs of ! and 10, 
respectively; LDLR 1 and LDLR 10, FH hepatocytes infected with Ad.CBhLDLR at MOIs of 1 and 10, respectively; 
Hep, normal human hepatocytes; liver, extract prepared from normal human liver. In each experiment, lanes derived 
from normal hepatocytes and liver were from the same blot, but exposed three times longer than lanes derived from 
FH hepatocytes. 
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FH hepatocytes were analyzed for func- 
tional LDL receptor activity using an in 
situ assay that is based on the receptor- 
mediated uptake of fluorescent-labeled LDL. 
Figure 4 presents fluorescent micrographs 
of FH3 hepatocytes that were infected with 
Ad.CBlacZ at an MOI of 10 (panels A and 
B) and Ad .CBhLDLR at an MOI of 1 
(panels C and D) and 10 (panels E and F). 
No fluorescence was detected in the 
Ad.CMVlacZ-infected cells, with 75% of 
the cells demonstrating high levels of LDL 
uptake after exposure to Ad.CBhLDLR virus 
at an MOI equal to 10. 
The recombinant adenoviruses used in 
this study were disabled by deleting E l a  and 
Elb,  which are normally required to activate 
the expression of other viral genes. It is 
possible, however, that this block in activa- 
tion can be overcome by cellular factors or by 
exposing the cells to high MOIs of replica- 
tion defective adenovirus. Experiments in 
human bronchial xenografts using the same 
viruses have demonstrated a block in transi- 
Fig. 4. LDL uptake assay of infected FH hepatocytes. FH hepatocytes were infected two days after plating with 
Ad.CBlacZ at a MOI of 10 (A, B), or with Ad.CBhLDLR at a MOI of 1 (C, D) or 10 (E, F). Twenty-four hours after 
infection, cells were incubated with medium containing 10% calf lipoprotein-deficient serum and 10 ~g/ml diI-LDL 
for 4 h. Panels A, C, and E are phase-contrast pictures, and panels B, D, and F are the corresponding fields viewed 
using fluorescence optics. 
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tion from early to late transcriptional units 
with high level expression of the early gone 
E2a (20). Similar techniques of immunocyto- 
chemistry were used to study the expression 
of adenoviral proteins in human hepatocytes 
exposed to adenoviruses. Expression of the 
early gone E2a and the late gone L5 was 
evaluated using antibodies to the correspond- 
ing gene products, the 72-kDa DNA binding 
protein and the fiber protein, respectively 
(Fig. 5). In each case, cells were harvested 
for analysis 16-18 h after exposure to virus. 
The 293 cells exposed to Ad.CMVlacZ 
(which replicates due to 293 cells providing 
the E1 gone products in trans) demonstrated 
DBP and fiber protein in virtually all cells 
(Fig. 5A-C); panel B shows punctate nuclear 
staining characteristic of DBP and panel C 
shows dark cytoplasmic staining characteris- 
tic of fiber. Human hepatocytes infected with 
wild-type Ad5 demonstrated high levels of 
DBP and trace levels of fiber in subpopula- 
tions of cells (Fig. 5D-F); no viral proteins 
were detected in human hepatocytes infected 
with the recombinant virus (Fig. 5G-I). 
In summary, we show that recombinant 
Fig. 5. Immunocytochemical analysis of transduced hepatocytes for viral protein expression. The 293 cells infected 
with Ad.CMVIacZ [a recombinant adenovirus in which lacZ is expressed from the CMV promoter (17), which 
replicates in 293 cells] at an MOI of 1 (panels A-C) and FH2 hepatocytes infected with either wild-type adenovirus 
(Ad5; panels D-F) or with the recombinant Ad.CBlacZ (panels G-I) at an MOI of I were harvested 16-18 h after 
infection. Samples were stained with no primary antibody (control; panels A, D, and G), or with antibodies 
recognizing the adenoviral gone products, the 72-kDa DNA binding protein (DBP; panels B, E, and H) or the fiber 
protein (panels C, F, and I). 
458 Kozarsky et al. 
adenoviruses based on human Ad5 are 
capable of very efficiently transducing genes 
into human hepatocytes without apparent 
cytopathic effects or expression of adenoviral 
proteins. This approach was used to fully 
correct the genetic defect in hepatocytes 
isolated from patients with FH. The encour- 
aging results in human hepatocytes along 
with previous studies in rodents suggest that 
recombinant adenoviruses may be useful in 
the development of in vivo liver-directed 
gene therapies in humans. However, several 
important issues remain regarding the utility 
of recombinant adenoviruses for gene therapy 
of FH. The effects of high-level constitutive 
expression of LDL receptor and its ability to 
catabolize LDL have to be addressed. In 
addition, it will be necessary to develop 
strategies for,achieving prolonged transgene 
expression in vivo. 
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